Its inhibition attenuates the viability of prostate cancer cells and decreases the transactivation activity of AR, which indicates that PRNCR1 could be involved in prostate carcinogenesis through an AR-mediated pathway. Here, PRNCR1 is linked to prostate carcinoma.